Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 20,148 shares of the business’s stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $61.54, for a total value of $1,239,907.92. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Clay B. Siegall also recently made the following trade(s):

  • On Monday, October 8th, Clay B. Siegall sold 20,148 shares of Seattle Genetics stock. The stock was sold at an average price of $77.39, for a total value of $1,559,253.72.
  • On Monday, September 17th, Clay B. Siegall sold 20,148 shares of Seattle Genetics stock. The stock was sold at an average price of $76.84, for a total value of $1,548,172.32.
  • On Monday, August 27th, Clay B. Siegall sold 25,514 shares of Seattle Genetics stock. The stock was sold at an average price of $74.23, for a total value of $1,893,904.22.
  • On Tuesday, August 21st, Clay B. Siegall sold 25,000 shares of Seattle Genetics stock. The stock was sold at an average price of $74.95, for a total value of $1,873,750.00.

Shares of Seattle Genetics stock traded down $2.50 on Friday, hitting $58.06. The stock had a trading volume of 724,404 shares, compared to its average volume of 1,275,881. Seattle Genetics, Inc. has a twelve month low of $47.75 and a twelve month high of $84.37.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings results on Thursday, October 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.15). The company had revenue of $169.42 million for the quarter, compared to analyst estimates of $164.75 million. Seattle Genetics had a negative return on equity of 19.13% and a negative net margin of 26.58%. On average, analysts anticipate that Seattle Genetics, Inc. will post -1.45 EPS for the current year.

Several research firms have recently commented on SGEN. Needham & Company LLC upped their target price on Seattle Genetics from $74.00 to $79.00 and gave the company a “buy” rating in a research report on Monday, July 30th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $75.00 target price on shares of Seattle Genetics in a research report on Friday, July 27th. HC Wainwright reaffirmed a “buy” rating and issued a $98.00 target price (up previously from $77.00) on shares of Seattle Genetics in a research report on Friday, July 27th. BidaskClub downgraded Seattle Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 18th. Finally, TheStreet downgraded Seattle Genetics from a “c” rating to a “d+” rating in a research report on Thursday, October 25th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $77.77.

A number of large investors have recently modified their holdings of the stock. IFM Investors Pty Ltd grew its position in Seattle Genetics by 14.6% during the third quarter. IFM Investors Pty Ltd now owns 5,992 shares of the biotechnology company’s stock worth $462,000 after buying an additional 762 shares in the last quarter. Aperio Group LLC grew its position in Seattle Genetics by 2.8% during the third quarter. Aperio Group LLC now owns 28,952 shares of the biotechnology company’s stock worth $2,233,000 after buying an additional 802 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in Seattle Genetics during the third quarter worth approximately $104,000. Teacher Retirement System of Texas grew its position in Seattle Genetics by 6.1% during the second quarter. Teacher Retirement System of Texas now owns 29,647 shares of the biotechnology company’s stock worth $1,968,000 after buying an additional 1,704 shares in the last quarter. Finally, OLD Mutual Customised Solutions Proprietary Ltd. acquired a new stake in Seattle Genetics during the second quarter worth approximately $139,000.

TRADEMARK VIOLATION WARNING: “Seattle Genetics, Inc. (SGEN) Insider Clay B. Siegall Sells 20,148 Shares of Stock” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/10/seattle-genetics-inc-sgen-insider-clay-b-siegall-sells-20148-shares-of-stock.html.

About Seattle Genetics

Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.

Read More: Stock Symbols and CUSIP Explained

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.